Skip to main content

Rydym wedi cadw rhai ffeiliau o'r enw cwcis ar eich dyfais. Y cwcis hyn yw:

  • Hanfodol ar gyfer y safle i weithio
  • Helpu i wella ein gwefan drwy gasglu ac adrodd gwybodaeth am sut rydych chi'n ei defnyddio

Hoffem hefyd arbed rhai cwcis i helpu i deilwra cyfathrebu.

BETA
Rydych yn edrych ar fersiwn wedi'i ddiweddaru o'r gwasanaeth hwn - bydd eich adborth yn ein helpu i'w wella.

Hysbysiad o Gontract

Process and Impact Evaluation

  • Cyhoeddwyd gyntaf: 29 Gorffennaf 2023
  • Wedi'i addasu ddiwethaf: 29 Gorffennaf 2023
  • Efallai na fydd y ffeil hon yn gwbl hygyrch.

  •  

Nid yw'r prynwr yn defnyddio'r wefan hon i weinyddu'r hysbysiad.

I gofnodi eich diddordeb neu gael gwybodaeth neu ddogfennau ychwanegol, darllenwch y cyfarwyddiadau yn Nhestun Llawn yr Hysbysiad. (NODER: Nid oes angen ymateb i Hysbysiadau Dyfarnu Contractau a Hysbysiadau Gwybodaeth Ymlaen Llaw fel arfer)

Rydych yn gweld hysbysiad sydd wedi dod i ben.

Cynnwys

Crynodeb

OCID:
ocds-h6vhtk-03eb5f
Cyhoeddwyd gan:
Genomics England
ID Awudurdod:
AA78457
Dyddiad cyhoeddi:
29 Gorffennaf 2023
Dyddiad Cau:
08 Medi 2023
Math o hysbysiad:
Hysbysiad o Gontract
Mae ganddo ddogfennau:
Nac Ydi
Wedi SPD:
Nac Ydi
Mae ganddo gynllun lleihau carbon:
AMH

Crynodeb

Two key components for which we require specific expertise in implementation science, behavioural science, health informatics and health economics are:

• Process Evaluation - will address research questions focusing specifically on whether the programme is acceptable and feasible. It will assess study delivery and processes to inform decision making for a possible future clinical service.

• Impact Evaluation - will address possible benefits and harms to:

o Stakeholders – including participants, Health Care professionals, and the public

o The System – including impact on existing newborn screening programmes and the impact on WGS for other patients as well as understanding comparative costs on the health care system.

o Experiences and Attitudes – including participants, the public and 3rd sector organisations.

Genomics England will act as sponsor for the Generation Study and associated evaluation work. Genomics England is ultimately accountable for the research of which this evaluation forms part. The successful Tenderer will be responsible for design and delivery of all research related activities pursuant to the bid, including but not limited to the delivery of documents for the HRA and any other relevant regulatory bodies (where necessary).

Testun llawn y rhybydd

Hysbysiad contract

Adran I: Endid contractio

I.1) Enw a chyfeiriad

Genomics England

One Canada Square

London

E14 5AB

UK

Ffôn: +44 2078825030

E-bost: supplier.engagement@genomicsengland.co.uk

NUTS: UKI

Cyfeiriad(au) rhyngrwyd

Prif gyfeiriad: www.genomicsengland.co.uk

I.3) Cyfathrebu

Mae'r dogfennau caffael ar gael ar gyfer mynediad uniongyrchol anghyfyngedig a llawn, yn rhad ac am ddim ar:

https://genomicsengland.bravosolution.co.uk


Gellir cael gwybodaeth ychwanegol o'r cyfeiriad uchod


Rhaid anfon tendrau neu geisiadau i gymryd rhan yn electronig at:

https://genomicsengland.bravosolution.co.uk


Rhaid anfon tendrau neu geisiadau i gymryd rhan i'r cyfeiriad uchod:


I.4) Y math o awdurdod contractio

Corff a lywodraethir gan gyfraith gyhoeddus

I.5) Prif weithgaredd

Iechyd

Adran II: Gwrthrych

II.1) Cwmpas y caffaeliad

II.1.1) Teitl

Process and Impact Evaluation

Cyfeirnod: GEL-SR-534-22

II.1.2) Prif god CPV

73210000

 

II.1.3) Y math o gontract

Gwasanaethau

II.1.4) Disgrifiad byr

Genomics England’s Generation Study aims to explore the benefits, challenges, and practicalities of offering whole genome sequencing to newborns, to accelerate diagnosis and access to treatment for rare genetic conditions. The programme funding was confirmed on 13 December 2022 with £105 million of funding to support it. Should it prove beneficial for participants and the wider health service, the study could pave the way for what would be the world’s first national newborn screening programme to incorporate whole genome sequencing.

The outcome for this project is for Genomics England to work in partnership with an organisation or group of organisations with the specific expertise to deliver the Generation Study evaluation. The Generation Study will:

1. evaluate the scientific and clinical utility and validity, operational feasibility, and impact on the NHS of using Whole Genome Sequencing to screen for a large number of childhood-onset rare genetic conditions and provide ongoing patient support

2. understand how, with consent, newborns’ genomic and health data could be used for research to enable new diagnostic discoveries and treatments to be developed

3. explore the potential risks, benefits, and broader implications of storing an individual’s genome over their lifetime (e.g., potential for preventative steps, personalised risk-based screening in later life etc.)

Please note that this tender seeks a partner to evaluate the first of these three aims only.

II.1.6) Gwybodaeth am lotiau

Mae’r contract hwn wedi’i rannu’n lotiau: Na

II.2) Disgrifiad

II.2.2) Cod(au) CPV ychwanegol

73000000

II.2.3) Man cyflawni

Cod NUTS:

UKI

II.2.4) Disgrifiad o’r caffaeliad

Two key components for which we require specific expertise in implementation science, behavioural science, health informatics and health economics are:

• Process Evaluation - will address research questions focusing specifically on whether the programme is acceptable and feasible. It will assess study delivery and processes to inform decision making for a possible future clinical service.

• Impact Evaluation - will address possible benefits and harms to:

o Stakeholders – including participants, Health Care professionals, and the public

o The System – including impact on existing newborn screening programmes and the impact on WGS for other patients as well as understanding comparative costs on the health care system.

o Experiences and Attitudes – including participants, the public and 3rd sector organisations.

Genomics England will act as sponsor for the Generation Study and associated evaluation work. Genomics England is ultimately accountable for the research of which this evaluation forms part. The successful Tenderer will be responsible for design and delivery of all research related activities pursuant to the bid, including but not limited to the delivery of documents for the HRA and any other relevant regulatory bodies (where necessary).

II.2.5) Meini prawf dyfarnu

Nid pris yw’r unig faen prawf dyfarnu a dim ond yn y dogfennau caffael y mae’r holl feini prawf wedi’u nodi

II.2.7) Hyd y contract, y cytundeb fframwaith neu’r system brynu ddynamig

Hyd mewn misoedd: 18

Gall y contract hwn gael ei adnewyddu: Ydy

Disgrifiad o’r adnewyddiadau:

An extension option of up to 12 months will be available for this contract

II.2.9) Gwybodaeth am y cyfyngiadau ar nifer yr ymgeiswyr a gaiff eu gwahodd

II.2.10) Gwybodaeth am amrywiadau

Derbynnir amrywiadau: Na

II.2.11) Gwybodaeth am opsiynau

Opsiynau: Na

II.2.13) Gwybodaeth am Gronfeydd yr Undeb Ewropeaidd

Mae'r broses gaffael yn gysylltiedig â phrosiect a/neu raglen a ariennir gan gronfeydd yr Undeb Ewropeaidd: Na

II.2.14) Gwybodaeth ychwanegol

Interested parties should register with Genomics England's e-tendering portal https://genomicsengland.bravosolution.co.uk and search for project_857 to access all relevant documentation.

Section III: Gwybodaeth gyfreithiol, economaidd, ariannol a thechnegol

III.1) Amodau ar gyfer cymryd rhan

III.1.2) Statws economaidd ac ariannol

Meini prawf dethol fel y’u nodir yn y dogfennau caffael


III.1.3) Gallu technegol a phroffesiynol

Meini prawf dethol fel y’u nodir yn y dogfennau caffael


III.2) Amodau sy’n gysylltiedig â’r contract

III.2.3) Gwybodaeth am y staff a fydd yn gyfrifol am gyflawni’r contract

Rhwymedigaeth i nodi enwau a chymwysterau proffesiynol y staff a glustnodwyd i gyflawni’r contract

Section IV: Gweithdrefn

IV.1) Disgrifiad

IV.1.1) Y math o weithdrefn

Gweithdrefn agored

IV.1.8) Gwybodaeth am Gytundeb Caffael y Llywodraeth (GPA)

The procurement is covered by the Government Procurement Agreement: Na

IV.2) Gwybodaeth weinyddol

IV.2.2) Terfyn amser i dendrau neu geisiadau i gymryd rhan ddod i law

Dyddiad: 08/09/2023

Amser lleol: 12:00

IV.2.4) Ym mha iaith/ieithoedd y gellir cyflwyno tendrau neu geisiadau i gymryd rhan

EN

IV.2.6) Yr isafswm cyfnod gofynnol i’r sawl sy’n tendro gynnal y tendr

Rhaid i’r tendr fod yn ddilys tan: 01/11/2023

IV.2.7) Amodau ar gyfer agor tendrau

Dyddiad: 08/09/2023

Amser lleol: 12:00

Section VI: Gwybodaeth ategol

VI.1) Gwybodaeth am ailddigwydd

Caffaeliad cylchol yw hwn: Na

VI.2) Gwybodaeth am lifau gwaith electronig

Defnyddir archebion electronig

Derbynnir anfonebau electronig

Defnyddir taliadau electronig

VI.3) Gwybodaeth ychwanegol

Interested parties should register with Genomics England's e-tendering portal https://genomicsengland.bravosolution.co.uk and search for project_857 to access all relevant documentation.

VI.4) Gweithdrefnau adolygu

VI.4.1) Corff adolygu

Public Procurement Review Service

London

UK

VI.5) Dyddiad anfon yr hysbysiad hwn

28/07/2023

Codio

Categorïau nwyddau

ID Teitl Prif gategori
73000000 Gwasanaethau ymchwil a datblygu a gwasanaethau ymgynghori cysylltiedig Ymchwil a Datblygu
73210000 Gwasanaethau ymgynghori ar ymchwil Gwasanaethau ymgynghori ar ymchwil a datblygu

Lleoliadau Dosbarthu

ID Disgrifiad
100 DU - I gyd

Cyfyngiadau Rhanbarthol ar y Rhybuddion

Mae’r prynwr wedi cyfyngu’r rhybuddion ar gyfer yr hysbysiad hwn i gyflenwyr yn y rhanbarthau canlynol.

ID Disgrifiad
Nid oes cyfyngiadau ar y rhybuddion ar gyfer yr hysbysiad hwn.

Ynglŷn â'r prynwr

Prif gyswllt:
supplier.engagement@genomicsengland.co.uk
Cyswllt gweinyddol:
N/a
Cyswllt technegol:
N/a
Cyswllt arall:
N/a

Gwybodaeth bellach

Dyddiad Manylion
Nid oes unrhyw wybodaeth bellach wedi'i lanlwytho.

0800 222 9004

Mae'r llinellau ar agor rhwng 8:30am a 5pm o ddydd Llun i ddydd Gwener.

Rydym yn croesawu galwadau'n Gymraeg.

We welcome calls in Welsh.